Management of Diabetic Patients with Hypercalcemia and Proteinuria

Diagnostic Approach

The American College of Physicians recommends investigating the cause of hypercalcemia urgently in diabetic patients, as it can indicate malignancy, primary hyperparathyroidism, or granulomatous disease 1, 2, 3.
Order intact PTH, PTHrP, serum protein electrophoresis with immunofixation, and 25-OH vitamin D levels to differentiate causes of hypercalcemia 1, 2.
The American Diabetes Association suggests quantifying proteinuria with urine albumin-to-creatinine ratio or 24-hour urine protein to distinguish between diabetic nephropathy and other causes 1, 2.

The American Diabetes Association recommends continuing or initiating metformin as first-line therapy for diabetic patients with preserved renal function (eGFR 91) 2, 6.
Add a second agent based on the algorithm: GLP-1 receptor agonist for weight loss and cardiovascular risk reduction, SGLT2 inhibitor for cardiovascular and renal protection, or DPP-4 inhibitor as alternative 2, 6.
Target A1C should remain <7% for patients with no documented cardiovascular disease and reasonable life expectancy 1, 3.

Check A1C every 3 months until stable at goal, then every 6 months 1, 2.
Implement self-monitoring of blood glucose focusing on fasting and 2-hour postprandial values 1, 7.
Annual urine albumin-to-creatinine ratio and eGFR monitoring for diabetic kidney disease progression 1, 2.

Do not attribute all findings to diabetes alone, as the triad of hypercalcemia, proteinuria, and polycythemia demands investigation for malignancy, particularly multiple myeloma 1, 3.
Do not start SGLT2 inhibitors without addressing hypercalcemia first, as these can cause volume depletion and worsen hypercalcemia 6, 4.
Do not delay hematology referral if polycythemia persists after hydration, as untreated polycythemia vera significantly increases thrombotic risk and mortality 1, 3.